Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10

This article was originally published in PharmAsia News

Executive Summary

HYDERABAD, India - Enthused by the success of its first monoclonal antibody Reditux - a copy of Genentech's Rituxan (rituximab) - India's Dr. Reddy's Labs is making a full throttle attempt to develop and launch copies of most blockbuster biotech drugs available in the international markets

You may also be interested in...



A Closer Look: Dr. Reddy’s Sees Global Leadership In Biosimilars Via Merck Serono Deal

Dr. Reddy’s CEO spoke with PharmAsia News to discuss the carefully crafted deal.

Dr. Reddy's Launches World's First Aranesp Biosimilar In India, Vows To Bring Out More

The Indian drug maker has officially kept its biosimilar pipeline secret but has indicated that it includes a pegylated molecule in late-stage clinical trials, two other products scheduled to enter clinical trials, and several others in early stage development.

Dr. Reddy's Launches World's First Aranesp Biosimilar In India, Vows To Bring Out More

The Indian drug maker has officially kept its biosimilar pipeline secret but has indicated that it includes a pegylated molecule in late-stage clinical trials, two other products scheduled to enter clinical trials, and several others in early stage development.

Related Content

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel